{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:13:27Z","timestamp":1791051207162,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.seminoncol.2006.01.029","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:06:25Z","timestamp":1148303185000},"page":"44-52","source":"Crossref","is-referenced-by-count":29,"special_numbering":"S5","title":["The Role of Alemtuzumab in the Management of T-Cell Malignancies"],"prefix":"10.1053","volume":"33","author":[{"given":"Claire","family":"Dearden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2006.01.029_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/46218","article-title":"Selecting and maintaining a diverse T-cell repertoire","volume":"402","author":"Goldrath","year":"1999","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00018-003-3224-3","article-title":"Molecular and cellular mechanisms of T cell development","volume":"61","author":"Bommhardt","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0037-1963(03)00132-X","article-title":"Classification of cytotoxic T-cell and natural killer cell lymphomas","volume":"40","author":"Jaffe","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(91)90228-M","article-title":"Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia","volume":"55","author":"Brito-Babapulle","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib5","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-001-0381-z","article-title":"T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype","volume":"80","author":"Sugimoto","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nm1097-1155","article-title":"Biallelic mutations in the ATM gene in T-prolymphocytic leukemia","volume":"3","author":"Stilgenbauer","year":"1997","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib9","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1182\/blood.V91.10.3920.3920_3920_3926","article-title":"Inactivation of the ATM gene in T-cell prolymphocytic leukemias","volume":"91","author":"Stoppa-Lyonnet","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/978-3-642-46870-4_9","article-title":"The ataxia telangiectasia gene in familial and sporadic cancer","volume":"154","author":"Yuille","year":"1998","journal-title":"Recent Results Cancer Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0165-4608(03)00104-3","article-title":"T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency","volume":"146","author":"Yamaguchi","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib12","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1073\/pnas.91.26.12530","article-title":"Identification of the TCL1 gene involved in T-cell malignancies","volume":"91","author":"Virgilio","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood.V87.5.1923.1923","article-title":"Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations","volume":"87","author":"Madani","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)00039-3","article-title":"The protooncogene TCL1 is an Akt kinase coactivator","volume":"6","author":"Laine","year":"2000","journal-title":"Mol Cell"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2004-01-0002","article-title":"A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories","volume":"104","author":"Herling","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/gcc.1141","article-title":"A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia","volume":"31","author":"Soulier","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0925-5710(98)00074-7","article-title":"14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia","volume":"68","author":"Kojima","year":"1998","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib18","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib19","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1080\/1042819021000040035","article-title":"Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?","volume":"43","author":"Delgado","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib20","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody","volume":"15","author":"Pawson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib23","first-page":"2378","article-title":"Very high response rates in previously untreated T-cell Prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy","volume":"102","author":"Dearden","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib24","first-page":"2495","article-title":"T-PLL-1 Protocol of the German CLL Study Group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first line treatment in T-PLL","volume":"102","author":"Hopfinger","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib25","series-title":"Clinical outcome of stem cell transplantation (SCT) in patients with T cell prolymphocytic leukaemia (T-PLL) previously treated with alemtuzumab","author":"Krishnan","year":"2005"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11864-005-0003-4","article-title":"Prolymphocytic leukemia","volume":"6","author":"Absi","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1054\/blre.1999.0118","article-title":"Current concepts","volume":"13","author":"Lamy","year":"1999","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1046\/j.1365-2141.2003.04365.x","article-title":"T-large granular lymphocyte lymphoproliferative disorder","volume":"121","author":"Dang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/0046-8177(94)90244-5","article-title":"In situ localization of Epstein-Barr virus encoded RNA in non-nasal\/nasopharyngeal CD56-positive and CD56-negative T-cell lymphomas","volume":"25","author":"Tsang","year":"1994","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib30","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.0007-1048.2001.03315.x","article-title":"Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia","volume":"116","author":"Wong","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-4608(02)00605-2","article-title":"Deletion 6q as a recurrent chromosomal aberration in T-cell large granular lymphocyte leukemia","volume":"139","author":"Man","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib32","first-page":"4768","article-title":"Recurrent genomic imbalances in T-cell large granular lymphocytes (T-LGL) leukemia detected by array-based comparative genomic hybridization (CGH)","volume":"102","author":"Skacel","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib33","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/blood-2002-08-2408","article-title":"Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C\/E and NKD2D killer cell receptors","volume":"101","author":"Bigouret","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)65454-5","article-title":"Comparative genomic hybridization analysis of natural killer cell lymphoma\/leukemia. Recognition of consistent patterns of genetic alterations","volume":"155","author":"Siu","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.2001.02561.x","article-title":"Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease","volume":"112","author":"Saunthararajah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib36","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood.V84.7.2164.2164","article-title":"Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate","volume":"84","author":"Loughran","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib37","first-page":"1467","article-title":"Treatment of T-cell large granular lymphocytic leukaemia","volume":"102","author":"Osuji","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.2003.04148.x","article-title":"Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity","volume":"120","author":"Sternberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib39","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2003.04609.x","article-title":"Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H)","volume":"123","author":"Ru","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib40","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2003-11-3951","article-title":"Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia","volume":"103","author":"Rosenblum","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/annonc\/mdh268","article-title":"CD56+ hematological neoplasms presenting in the skin","volume":"15","author":"Bekkenk","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.10381","article-title":"Complete remission in advanced blastic NK-cell lymphoma\/leukemia in elderly patients using the hyper-CVAD regimen","volume":"74","author":"Shapiro","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib43","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/sj.bmt.1704078","article-title":"Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation","volume":"31","author":"Ebihara","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/pbc.20034","article-title":"Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation","volume":"42","author":"Hyakuna","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bmt.1703796","article-title":"Unrelated bone marrow transplantation for Epstein-Barr virus-associated T\/NK-cell lymphoproliferative disease","volume":"31","author":"Okamura","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib46","first-page":"336","article-title":"HTLV-1 and associated adult T-cell leukemia\/lymphoma","volume":"7","author":"Mahieux","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib47","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1073\/pnas.79.15.4780","article-title":"Healthy carriers of a human retrovirus, adult T-cell leukemia virus (ATLV)","volume":"79","author":"Gotoh","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.V98.4.1200","article-title":"The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors","volume":"98","author":"Portis","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib49","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/sj.onc.1204304","article-title":"Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I","volume":"20","author":"Iwanaga","year":"2001","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib50","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1349-7006.2000.tb00892.x","article-title":"Identification of genes associated with the progression of adult T cell leukemia (ATL)","volume":"91","author":"Kohno","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428190109057925","article-title":"HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia","volume":"40","author":"Arima","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib52","first-page":"1481","article-title":"Chromosome abnormalities in adult T-cell leukemia\/lymphoma","volume":"52","author":"Kamada","year":"1992","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib53","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/309640a0","article-title":"Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells","volume":"309","author":"Seiki","year":"1984","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib55","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma","volume":"113","author":"Matutes","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10428190109057927","article-title":"The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia\/lymphoma","volume":"40","author":"White","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib57","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.thj.6200195","article-title":"A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol J"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.thj.6200374","article-title":"Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"5","author":"Hermine","year":"2004","journal-title":"Hematol J"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib59","first-page":"3348","article-title":"CCR4","volume":"102","author":"Ishida","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib60","first-page":"6453","article-title":"Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib61","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/sj.onc.1208979","article-title":"Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy","volume":"24","author":"Taylor","year":"2005","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib62","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1200\/jco.2005.23.16_suppl.6639","article-title":"Durable complete response of the human T-cell leukemia virus (HTLV-1) viral load (VL) with alemtuzumab in refractory adult T-cell leukemia (ATL)","volume":"28","author":"Porcu","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib63","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1046\/j.1365-2133.2000.03888.x","article-title":"CD8-positive juvenile onset mycosis fungoides","volume":"143","author":"Whittam","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib64","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.0022-202x.2001.01460.x","article-title":"Allelotyping in mycosis fungoides and Sezary syndrome","volume":"117","author":"Scarisbrick","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA)","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib66","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2003.10.669","article-title":"Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma","volume":"50","author":"McGinnis","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib68","first-page":"809","article-title":"Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides","volume":"84","author":"Rupoli","year":"1999","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib69","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib70","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib71","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib72","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib73","first-page":"37","article-title":"Pentostatin treatment of cutaneous T-cell lymphoma","volume":"14","author":"Dearden","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib74","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199709109162","article-title":"2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders","volume":"26","author":"Kong","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib76","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","article-title":"Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides","volume":"39","author":"Saleh","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib78","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib79","first-page":"2383","article-title":"HuMax-CD4, a fully human monoclonal antibody","volume":"102","author":"Obitz","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib80","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","article-title":"CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin\u2019s lymphomas","volume":"16","author":"Lundin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib81","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib82","first-page":"556","article-title":"Sezary syndrome responds to treatment with Campath-1H","volume":"98","author":"Foukaneli","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1385\/MO:20:4:389","article-title":"Mycosis fungoides\/Sezary syndrome","volume":"20","author":"Capalbo","year":"2003","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib84","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib85","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/blood-2004-11-4314","article-title":"Correspondence","volume":"105","author":"Lundin","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000077322","article-title":"Familial cutaneous mycosis fungoides","volume":"208","author":"Weder","year":"2004","journal-title":"Dermatology"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib87","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/00000478-200312000-00003","article-title":"Peripheral T-cell lymphomas expressing CD30 and CD15","volume":"27","author":"Barry","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib88","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/088922204773004833","article-title":"Peripheral T cell lymphoma with cytotoxic phenotype","volume":"20","author":"Ruco","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib89","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0002-9440(10)63742-X","article-title":"Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations","volume":"164","author":"Zettl","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib90","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0145-2126(02)00266-7","article-title":"High tumor necrosis factor-alpha levels in the patients with Epstein-Barr virus-associated peripheral T-cell proliferative disease\/lymphoma","volume":"27","author":"Mori","year":"2003","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib91","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0145-2126(02)00274-6","article-title":"The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas","volume":"27","author":"Dutcher","year":"2003","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib92","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/path.1346","article-title":"BCL-2 family proteins in peripheral T-cell lymphomas","volume":"200","author":"Rassidakis","year":"2003","journal-title":"J Pathol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib93","first-page":"512","article-title":"ALK-negative anaplastic large cell lymphomas represent a distinct entity","volume":"16","author":"J\u00f6hrens","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib94","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00277-002-0450-y","article-title":"A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin\u2019s lymphoma","volume":"81","author":"Pellatt","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib95","first-page":"1363","article-title":"Peripheral T cell lymphoma","volume":"22","author":"Musson","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib96","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/1042819021000006277","article-title":"Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas","volume":"43","author":"Lee","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib97","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V104.11.2640.2640","article-title":"Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin is an effective first-line regimen in peripheral T-cell lymphomas","volume":"104","author":"Weidmann","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib98","first-page":"321","article-title":"CHOP chemotherapy plus Campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL)","volume":"16","author":"Gallamini","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib99","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib100","first-page":"2384","article-title":"A pilot study of alemtuzumab (Anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma","volume":"102","author":"Enblad","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib101","first-page":"1372","article-title":"High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib102","first-page":"72","article-title":"Long-term follow-up of autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL)","volume":"16","author":"Rodriguez","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.029_bib103","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00277-002-0556-2","article-title":"Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation","volume":"81","author":"Kahl","year":"2002","journal-title":"Ann Hematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:22:52Z","timestamp":1627392172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775406000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":103,"alternative-id":["S0093775406000613"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2006.01.029","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}